For research and educational purposes only. Not medical advice.
Icatibant Reference
Educational, not medical advice reference for Icatibant: Immune; regulatory status, evidence posture, source review, and schedule notes. Also known as Firazy…
Reference summary
Icatibant is a label-verified bradykinin B2 receptor antagonist with FDA Phase 3 evidence in acute attacks of hereditary angioedema. pepSmart surfaces label-reference content only.
- Categories
- Immune
- Aliases
- Firazyr, JE 049, HOE 140, Bradykinin B2 antagonist
- Evidence posture
- human - Approved for an extremely narrow rare-disease indication (acute HAE attacks). Not a chronic-use or wellness drug. Self-administration in HAE is patient-training-dependent; clinicians remain involved per label. Laryngeal attacks should be managed in a healthcare setting.
- Regulatory status
- FDA-approved prescription medication (Firazyr). Initial US approval 2011. Indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults aged 18 years or older. Synthetic decapeptide selective bradykinin B2 receptor antagonist. Prescription-only.
- Content review status
- label verified